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Glutathione (GSH) derives from cysteine and plays a key role in redox status. GSH synthesis is determined mainly by cysteine
availability and γ-glutamate cysteine ligase (γGCL) activity. Because PPARα activation is known to control the metabolism of
certain amino acids, GSH synthesis from cysteine and related metabolisms were explored in wild-type (WT) and PPARα-null
(KO) mice, fed diets containing either saturated (COCO diet) or 18:3 n-3, LIN diet. In mice fed the COCO diet, but not in those
fed the LIN diet, PPARα deﬁciency enhanced hepatic GSH content and γGCL activity, superoxide dismutase 2 mRNA levels, and
plasma uric acid concentration, suggesting an oxidative stress. In addition, in WT mice, the LIN diet increased the hepatic GSH
pool, without eﬀect on γGCL activity, or change in target gene expression, which rules out a direct eﬀect of PPARα. This suggests
that dietary 18:3 n-3 may regulate GSH metabolism and thus mitigate the deleterious eﬀects of PPARα deﬁciency on redox status,
without direct PPARα activation.
1.Introduction
PPARα is a major regulator of the macronutrient metab-
olism, especially during the fed-to-fasting transition [1].
Formerly, PPARα has been involved in the regulation of lipid
metabolism, including cellular uptake of fatty acids, intra-
cellular fatty acid binding and activation, microsomal ω-
oxidation, β-oxidation and ketogenesis, and synthesis of li-
poproteins [2, 3]. Later on, PPARα eﬀects have been shown
to extend to a number of target genes involved in the metab-
olismofglucose,glycerolandglycogen,andbileacids,aswell
asininﬂammation,detoxiﬁcation,andhepatocarcinogenesis
[4, 5]. More recently, PPARα has also been shown to play a
role in amino acid metabolism, through the regulation of a
number of hepatic target genes involved in transamination,
deamination, and urea synthesis [6–8].
Beyond nutritional situations, interest in PPARα eﬀects
on amino acids metabolism can also be considered in light of
the involvement of speciﬁc amino acids in physiopatholog-
ical processes associated with the metabolic syndrome. We
have recently shown that PPARα deﬁciency decreases whole
body nitric oxide (NO) synthesis from arginine, suggesting a
beneﬁcial eﬀect of PPARα on vascular function [9]. Cysteine
is a second amino acid of which metabolism might be of
importance in the context of metabolic syndrome. Indeed,
cysteine is the rate-limiting substrate for the synthesis of
glutathione (GSH) [10], a major endogenous antioxidant,
protecting cells from reactive oxygen species (ROS). Most of
the GSH is utilized in antioxidant defence via the glutathione
peroxidase (GPX) enzyme family to neutralize ROS and pro-
tect the body from their noxious eﬀect [11]. GSH synthesis is
a two-step process. The ﬁrst rate-limiting step is the conden-
sation of cysteine and glutamate to γ-glutamylcysteine and is
catalyzed by γ-glutamate cysteine ligase (γGCL). While GSH
synthesis occurs in every tissue, the liver plays a prominent
role in whole body GSH ﬂux [12]. A growing number
of studies support a link between glutathione synthesis
and utilization and the metabolic syndrome. Alterations
in glutathione status and utilisation are long-recognized
hallmarks of metabolic syndrome-associated oxidative stress2 PPAR Research
[13–17]. In parallel, fuelling glutathione synthesis through
an extra cysteine supply has been shown to alleviate insulin
resistance and oxidative stress in animal models of the
metabolic syndrome [18, 19].
Despite that PPARα activation enhances ROS generation
by activating fatty acid and β-a n dω-oxidation, it can also
promote ROS clearance through increased expression and/or
activity of antioxidant enzymes, such as catalase (CAT) and
superoxide dismutase (SOD) [20–23]. Accordingly, PPARα
deﬁciency decreases the activity of the same enzymes [23].
However, little is known regarding the role of PPARα
in hepatic metabolism of GSH. In fasted mice, PPARα
deﬁciency reduced hepatic GSH level and GPX activity [23].
Consistently, ﬁbrate treatment increased erythrocyte GPX
activity in human [24] and hepatic GSH content in the
mouse [25]. A few studies have also addressed the eﬀect
of n-3 polyunsaturated fatty acids (PUFA), natural PPARα
ligands, on GSH metabolism. In a rat model of chronic
heartfailure,n-3fattyacidtreatmentincreasedcardiacγGCL
contentandactivity,increasedtotalandreducedglutathione,
and decreased oxidized glutathione [26]. As concerns the
destructionofROS,theeﬀectsofn-3PUFAsupplementation
in the rat are inconsistent, with GPX activity being decreased
[27]o rn o tc h a n g e d[ 28]. In cultured human ﬁbroblasts,
DHA (22:6 n-3) induced expression and activity of γGCL,
as well as intracellular GSH content [29]. However, none of
these studies provided a direct evidence for a role of PPARα
in the modulation of GSH metabolism by n-3 fatty acids.
The ﬁrst and main objective of the present study was to
investigatetheeﬀectsofPPARαinvalidationintheregulation
of GSH metabolism by using wild-type (WT) and PPARα-
deﬁcient mice (KO). We have shown previously in the mouse
that a number of hepatic genes known to be regulated
essentially via PPARα were upregulated by α-linolenic acid
(ALA, 18:3 n-3) as they are by its long-chain derivatives.
This was observed in WT mice fed rather high-fat diets [30]
but also in WT mice fed low-fat diets, albeit to a lesser
extent [31]. For these reasons, as a secondary objective,
we aimed to assess the contribution of dietary n-3 PUFA
to PPARα activation, by exposing mice to contrasted diets,
containing mostly either saturated FA or ALA. We explored
GSH synthesis from cysteine, as well as hepatic thiol content
and mRNA levels of enzymes involved in the protection
against oxidative damages.
2.MaterialsandMethods
2.1. Animals and Diets. Male PPARα-deﬁcient mice [32]
were supplied by the ToxAlim laboratory (UR66, INRA,
Toulouse), in which several additional rounds of backcross-
ing have been performed initially to increase the C57BL/6J
genetic background and to generate the animals used [33].
Wild type male C57BL/6J mice were obtained from Charles
River (L’Arbresle, France). In vivo studies were conducted
under European Union guidelines for the use and care of
laboratory animals.
Twenty-eight 6-7-week-old mice were bred in INRA’s
facility in Paris and housed collectively on wood litter, at
22 ± 2◦C under 12-h light/dark cycles (light on at 06:00am).
They were fed ad libitum a standard pelleted diet (Teklad
20-18S, Harlan, Gannat, France) and acclimated to local
conditions for 4 weeks. At 10-11 weeks of age, mice were fed
during 8 weeks one of the two experimental diets diﬀering
in their fatty acid proﬁle (LIN or COCO diet, as described
below). They had free access to food and tap water. Food
consumption (as assessed per collective cage and expressed
relatively to the mean body weight of mice in each cage) and
individual body weight were recorded weekly.
Diets were provided as pellets by UPAE-INRA (Jouy-en-
Josas, France) as described previously [31]. The calculated
composition (in weight) of the two diets was 21.0% protein,
69.2% carbohydrate, 4.8% lipid, 4.0% vitamins, and 4.0%
minerals. The experimental diets were isoenergetic, with
lipids providing 11.3% of total energy intake. The choice
of a low fat diet was based on the results of a previous
nutrigenomic study of some of the present authors, showing
signiﬁcant eﬀects of PPARα deﬁciency on lipid and xeno-
biotic metabolism in mice fed the same diets as in the
present study [31]. Besides, in our previous studies, Cyp4a14
gene, exhibiting a PPRE sequence and being speciﬁcally
activated by PPARα pure agonists [34], was signiﬁcantly
more expressed in WT mice than in KO mice fed a low fat
diet rich in 18:3 n-3 [9, 31]. This indicated that even a low
dietary amount of n-3 PUFA was able to activate PPARα,
which justiﬁed the choice of the dietary conditions. Oils
used for experimental diet preparation were hydrogenated
coconut oil for a saturated FA-rich diet (SFA, COCO diet)
and linseed oil for a ALA-rich oil (LIN diet). Their fatty
acid composition was (in weight %): 99.6% SFA, 0.3%
monounsaturated FA (MUFA), and 0.1% PUFA for the
COCO diet; 9.0% SFA, 18.0% MUFA, and 72.9% PUFA
(58% ALA) for the LIN diet [31].
2.2. Experimental Design. At the end of the experimental
period, mice were fasted for 5h, then weighed and anes-
thetized with combined xylazine/ketamine solution. Blood
was taken by cardiac puncture, and mice were then killed
by exsanguination. Plasma was separated by centrifugation
(1,700∗g, 20min, 4◦C) and aliquots were stored at −80◦C.
The abdominal cavity was then opened, and the liver was
removedandweighed.Severalliversamplesweresnapfrozen
in liquid nitrogen and stored at −80◦C. Epididymal adipose
tissue (EpAT, visceral localization) and inguinal adipose
tissue (IngAT, subcutaneous localization) were removed and
weighed.
2.3. Biochemical Analyses. Blood glucose concentration was
determined with an Accu-Chek glucometer (Roche Diag-
nostics, Meylan, France). Plasma cholesterol, triglycerides,
and uric acid were determined by colorimetric enzymatic
methods using commercial kits (Bio-Merieux, Craponne,
France), adapted for use in a 96-well microplate reader
(Molecular Devices, Saint-Gr´ egoire, France). Plasma amino
acids were determined by ion-exchange chromatography
with postcolumn ninhydrine derivatisation on an Amino-
tac JLC-500/V (Jeol, Tokyo, Japan). Plasma concentrationsPPAR Research 3
Table 1: Primer sequences used in quantitative RT-PCR analysis.
Gene name Abbreviation Ref Seq Forward primer Reverse primer
Glutathione peroxidase 1
(GPX1)
Gpx1 NM 008160 GACACCAGGAGAATGGCAAGA ACCATTCACTTCGCACTTCTCA
Cysteine dioxygenase
(CDO)
Cdo NM 033037 GATACATGCCACGCCTTTGA CCTGAAGTTGTAAATGGAGTCCTGAT
Catalase (CAT) Cat NM 009804 GCCAGAAGAGAAACCCACAGACT CACTGAACAAGAAAGAAACCTGATG
Glutamate cysteine ligase
(γGCL), catalytic subunit
Gclc NM 010295 GGAGGCGATGTTCTTGAGACTCT CCTTCGATCATGTAACTCCCATACT
Glutamate-cysteine ligase
(γGCL), modiﬁer subunit
Gclm NM 008129 GGCCTCCTGCTGTGTGATG GCCTCAGAGAGCAGTTCTTTCG
Superoxide dismutase 1
(SOD1)
Sod1 NM 011434.1 GTGCAGGGAACCATCCACTT GTCCTGACAACACAACTGGTTCA
Superoxide dismutase 2
(SOD2)
Sod2 NM 013671 GCTCTGGCCAAGGGAGATG TGATTAATATGTCCCCCACCATT
CD68 antigen (CD68) Cd68 NM 009853.1 CATCAGAGCCCGAGTACAGTCTACC AATTCTGCGCCATGAATGTCC
Chemokine (C-C motif)
ligand 2 (MCP1)
Ccl2 NM 011333.3 GGCTCAGCCAGATGCAGTTAA CCAGCCTACTCATTGGGATCA
Serum amyloid A (SAA) Saa NM 009117.3 GCGAGCCTACACTGACATGA TTTTCTCAGCAGCCCAGACT
All primer sequences were designed using Primer Express (Applied Biosystems) software and were from Eurogentec (Eurogentec, Seraing, Belgium).
of adiponectin, plasminogen activator inhibitor-1 (PAI-
1), monocyte chemotactic protein-1 (MCP-1), leptin, and
insulin were determined using multiplexed immunoassays
(Millipore-Linco Research, St. Charles, USA) on a Bioplex-
200 analyzer (Bio-Rad Laboratories, Marnes-la-Coquette,
France).
2.4. Gene Expression. Total RNA was extracted from a liver
sample using Trizol reagent (Invitrogen, Carlsbad, USA),
and synthesis of cDNA was performed on 400ng of total
RNA using a high capacity cDNA reverse transcription kit,
based on the use of both oligodT and hexamers (Applied
Biosystems, Foster City, USA). The primers listed in Table 1
were used for quantitative PCR on a 7300 real-time PCR
system (Applied Biosystems), as described previously [35].
Gene expression was determined using the 2−ΔCt formula
where ΔCt = ( C tt a r g e tg e n e− Ct 18S).
2.5. Hepatic Thiol Concentrations. Total low-molecular wei-
ght thiols (cysteine, GSH, and cysteinylglycine (CysGly))
were analyzed using high-performance liquid chromatog-
raphy (HPLC) as described previously, with slight modiﬁ-
cations [36]. Brieﬂy, 50mg of liver samples were homoge-
nized in 950μL of 0.1M phosphate buﬀer and centrifuged
(3,000∗g, 5min). A small volume of supernatant was
removed for subsequent protein assay with the Pierce bici-
nchoninic acid (BCA) Assay Kit (Pierce, Rockford, USA).
Sixty μL of the supernatant were reduced with 0.66vol of
triphenylphosphine (10% in dimethylformamide) depro-
teinized by 2vol of 10% TCA and derivatized by 3% 4-
(aminosulfonyl)-7-ﬂuoro-2,1,3-benzoxadiazole at pH 9.0.
After 1 hour incubation at 4◦C, derivatization was stopped
by adding 25μL of 4mMHCL. N-acetylcysteine was added
in every sample as an internal standard. Thiol separation was
achievedat45◦ConaKromasilc18column(15cm×4.6mm
id., 3.5μm) with a mobile phase consisting in 90% 100mM
citrate buﬀer pH 4.0 and 10% methanol. External standards
of GSH, cysteine, and CysGly were used for the identiﬁcation
and quantiﬁcation of thiols in liver homogenates. Results
were normalized for liver weight or protein content.
2.6. Hepatic γGCL Activity. Liver γGCL activity was assessed
in liver homogenate using a ﬂuorescence-based method
as described previously [37]. Brieﬂy, a cytosolic fraction
was prepared from a 50mg liver homogenate by successive
centrifugation (10,000∗g, 10min, 4◦C and 15,000∗g, 5min,
4◦C). Fifty μL of this cytosolic fraction were preincu-
bated for 5min at 37◦C with 1vol of reaction medium
consisting in (ﬁnal concentration): 133mM Tris, 13.3mM
ATP, 6.66mM glutamic acid, 0.66mM serine, 0.66mM
EDTA, 6.66mM sodium borate and 13.3mM MgCl2.T h e
reaction was started by the addition of 50μL of cysteine
(0.66mM, ﬁnal concentration) and stopped after 20 minutes
at 37◦Cw i t h5 0 μL of 200mM sulfosalicylic acid followed
by centrifugation at 2,000×g. For derivatization, 20μLo f
the resulting supernatant were incubated with 180μLo f
10mM 2,3-naphthalenedicarboxaldehyde (NDA) solution,
to form NDA-γ-glutamylcysteine. Fluorescence intensity (εex
472nm −εem 528nm) was measured on a ﬂuorescence plate
reader (CytoFluor 4000, Applied Biosystems) and quantiﬁed
using standard curves of NDA-GSH. Results were corrected
for initial GSH content and normalized for liver weight or
protein concentration of the cytosolic fraction.
2.7. StatisticalAnalyses. Data are presented asmeans ± SEM.
They were analysed using the SAS program (SAS Institute,
Cary, USA). Diﬀerencesbetweentreatmentsandinteractions
were tested with a two-way ANOVA with genotype and diet4 PPAR Research
Table 2: Markers of PPARα deﬁciency in WT and PPARα-null (KO) mice fed diets containing either saturated FA (COCO diet) or ALA (LIN
diet) for 8 weeks.
WT KO P values
COCO LIN COCO LIN ANOVA Genotype
(G)
Diet
(D)
Interaction
G∗D
Body weight (g) 29.5 ± 0.5b 29.6 ± 0.5b 36.7 ± 1.0a 32.7 ± 1.5b 0.0001 0.0001 0.0379 0.0261
Liver weight (g) 1.07 ± 0.04b 1.07 ± 0.06b 1.55 ± 0.08a 1.04 ± 0.04b <0.0001 0.0004 0.0001 0.0001
Liver weight (%) 3.88 ± 0.10b 3.88 ± 0.25b 4.50 ± 0.12a 3.71 ± 0.12b 0.0007 0.1403 0.0112 0.0123
EpAT weight (%) 2.31 ± 0.16b 2.58 ± 0.19ab 3.47 ± 0.28a 2.91 ± 0.40ab 0.0013 0.0038 0.5062 0.0720
IngAT weight (%) 1.46 ± 0.19b 1.78 ± 0.12ab 2.50 ± 0.23a 1.79 ± 0.22ab 0.0063 0.0090 0.3293 0.0102
Blood glucose
(g/L) 1.94 ± 0.18b 1.83 ± 0.21b 1.48 ± 0.17ab 1.17 ± 0.12a 0.0001 0.0001 0.1892 0.4690
Plasma TG
(mg/dL) 0.25 ± 0.02a 0.30 ± 0.03ab 0.39 ± 0.01b 0.36 ± 0.05ab 0.0231 0.0039 0.7881 0.3064
Plasma CT
(mgd/L) 0.75 ± 0.02b 0.62 ± 0.05b 1.20 ± 0.07a 0.84 ± 0.11b 0.0001 0.0001 0.0015 0.0823
Values are means ± standard errors for 7 mice per group. Mean values within a row sharing a same superscript letter, or without superscript letter, were not
signiﬁcantly diﬀerent at P < 0.05.
as factors, using the GLM procedure. When the genotype
and/or diet factor was signiﬁcant, diﬀerences between means
were tested for signiﬁcance using the posthoc Tukey-Kramer
procedure. Signiﬁcance level was set at P < 0.05.
3. Results
3.1. Markers of PPARα Deﬁciency in Relation to Dietary
Treatment (Table 2). BodyweightwashigherintheKOmice.
Throughout the 8 weeks of the experiment, individual daily
foodintake(ing,andasestimatedfromtotalfoodconsumed
per cage) was higher in KO mice, but was similar to the WT
mice when corrected for the body weight (130 ± 14mg/g
body weight per day, whatever the genotype or the diet).
This indicated that the higher body weight of the KO groups
did not diﬀer primarily from a higher food intake. In WT
mice, the fatty acid composition of the diets did not aﬀect
the markers of the metabolic syndrome. PPARα deﬁciency
resulted in higher body and liver weights, as well as in
adipose tissue proportion than in WT mice. Post-hoc analysis
showed that this genotype eﬀect was signiﬁcant only in the
COCO-fed mice, and not in the LIN-fed ones. In contrast,
there was no overall eﬀect of PPARα deﬁciency on liver
proportion but a signiﬁcant genotype ∗ diet interaction, so
that post-hoc analyses revealed that the liver proportion was
signiﬁcantly increased by PPARα deﬁciency the COCO-fed
group, and not in the LIN-fed one. Similarly, the higher
plasma concentrations of triglyceride and cholesterol found
in the KO mice were more pronounced in the COCO-
fed group than in the LIN-fed one. In contrast, when
compared to their WT counterparts, KO mice exhibited a
lower glycemia, this eﬀect being more pronounced in mice
fed the LIN diet.
3.2. GSH Metabolism Related Parameters
3.2.1. Hepatic Thiols Status (Table 3). Hepatic GSH con-
centration and pool varied according to the experimental
conditions, with a strong interaction between the genotype
and the diet (P < 0.001). In WT mice, GSH concentration
and pool were 40% higher in those fed the LIN diet than
in those fed the COCO diet. PPARα deﬁciency resulted in
increased concentration and pool of GSH in the COCO-fed
mice, while it did not aﬀect the LIN-fed diet ones. Hepatic
concentration and pool of cysteine and CysGly were much
lower than those of GSH and were neither aﬀected by PPARα
deﬁciency nor by the diet.
3.2.2. Hepatic γGCL Activity (Figure 1)a n dm R N AL e v e l s
of γGCL and CDO (Table 4). In WT mice, the fatty acid
composition of the diets did not inﬂuence either spe-
ciﬁc or total γGCL activity. PPARα deﬁciency signiﬁcantly
increased γGCL speciﬁc activity (Figure 1(a)) and total
activity (Figure 1(b)). The post-hoc analysis showed that the
eﬀect of PPARα deﬁciency on γGCL was signiﬁcant only in
the LIN-fed mice for the speciﬁc activity and in the COCO-
fed mice for the total activity. Hepatic mRNA level of γGCL
and CDO was not aﬀected by either PPARα deﬁciency or the
diet (Table 4).
3.2.3. Plasma Amino Acid Concentrations (Table 5). Among
amino acids related to cysteine metabolism, PPARα deﬁ-
ciency was associated with a signiﬁcantly higher plasma
concentration of methionine and lower concentration of
glycine and taurine. Plasma concentration of glutamic acid
and cysteine was not aﬀected by the genotype. None of the
plasma concentrations was inﬂuenced by the diet.
3.3. Oxidative Stress and Inﬂammatory Status
3.3.1. Hepatic mRNA Levels of Antioxidant Enzymes and of
InﬂammatoryMarkers(Table 4). HepaticmRNAlevelsofthe
genes coding for GPx (Gpx1), CAT (Cat), and Cu/ZnSOD
(Sod1) were not aﬀected by PPARα deﬁciency, while PPARα
deﬁciency signiﬁcantly increased the mRNA level coding forPPAR Research 5
Table 3: Hepatic thiols concentrations and pools in WT and PPARα-null (KO) mice fed diets containing either saturated FA (COCO diet)
or ALA (LIN diet) for 8 weeks.
WT KO P values
COCO LIN COCO LIN ANOVA Genotype
(G)
Diet
(D)
Interaction
G∗D
GSH (μmol/g
of protein) 3112 ± 180b 5138 ± 412a 5201 ± 509a 3892 ± 382ab 0.0013 0.2815 0.3569 0.0003
Cysteine
(μmol/g of
protein)
274 ± 91.8 190 ± 66.0 211 ± 55.8 243 ± 55.8 0.8377 0.9432 0.7061 0.4144
CysGly
(μmol/g of
protein)
97.5 ± 5.80 83.6 ± 12.7 102 ± 20.5 93.5 ± 8.14 0.8012 0.6243 0.4461 0.8514
GSH (μmol/
liver) 439 ± 31.3b 774 ± 77.2ac 1031 ± 118a 544 ± 80.7bc 0.0002 0.0367 0.3590 <.0001
Cysteine
(μmol/ liver) 40.2 ± 16.0 29.3 ± 10.6 41.3 ± 10.1 33.2 ± 7.62 0.8614 0.8304 0.4181 0.9034
CysGly (μmol/
liver) 14.2 ± 1.24 13.1 ± 2.03 20.0 ± 3.49 12.9 ± 1.19 0.1456 0.2600 0.1099 0.2383
Values are means ± standard errors for 7 mice per group. Mean values within a row sharing a same superscript letter, or without superscript letter, were not
signiﬁcantly diﬀerent at P < 0.05.
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Figure 1: Hepatic GCL activity in WT and PPARα-deﬁcient (KO) mice fed diets containing either saturated FA (COCO diet) or ALA (LIN
diet) for 8 weeks. Values are expressed as nmol/mg of protein/h for speciﬁc activity (a) and as mmol/liver/h for total activity (b). They
are means ± standard errors for 7 mice per group, ∗∗KO group signiﬁcantly diﬀerent from WT group P < 0.01. Columns sharing a same
superscript letter, or without superscript letter, were not signiﬁcantly diﬀerent at P < 0.05.
MnSOD (Sod2). None of these mRNA levels was inﬂuenced
by the diet, whatever the genotype.
CD68 mRNA level was signiﬁcantly higher in KO mice
thaninWTones.Post-hoc analysisshowedthatthisgenotype
eﬀect was borne by the mice fed the LIN diet essentially. SAA
and MCP1 mRNA levels were also numerically higher in KO
mice, but the diﬀerence was not statistically signiﬁcant (P =
0.0684 for SAA and 0.0829 for MCP1).
3.3.2. Plasma Concentration of Uric Acid (Figure 2). In WT
mice,thefattyacidcompositionofthedietsdidnotinﬂuence6 PPAR Research
Table 4: Hepatic mRNA levels of cysteine and glutathione metabolism key genes, and of inﬂammatory markers, in WT and PPARα-null
(KO) mice fed diets containing either saturated FA (COCO diet) or ALA (LIN diet) for 8 weeks (arbitrary units).
WT KO P values
COCO LIN COCO LIN ANOVA Genotype
(G)
Diet
(D)
Interaction
G∗D
Glutamate cysteine
ligase (γGCLc),
catalytic subunit
0.22 ± 0.04 0.30 ± 0.07 0.22 ± 0.05 0.13 ± 0.02 0.1583 0.0941 0.9836 0.1183
Glutamate cysteine
ligase (γGCLm),
modiﬁer subunit
0.68 ± 0.11 0.65 ± 0.07 0.55 ± 0.07 0.63 ± 0.17 0.8840 0.5255 0.8070 0.6317
Cysteine
dioxygenase (CDO)
3.84 ± 0.61 2.24 ± 0.16 2.22 ± 0.38 3.92 ± 1.02 0.1193 0.8885 0.9780 0.0181
Glutathione
peroxidase 1 (GPX1)
8.65 ± 1.58 9.32 ± 1.15 8.79 ± 1.55 9.54 ± 2.71 0.9857 0.9272 0.7211 0.9844
Catalase (CAT) 1.05 ± 0.28 0.97 ± 0.12 0.92 ± 0.22 0.71 ± 0.13 0.6463 0.3327 0.4750 0.7445
Superoxide
dismutase 1 (SOD1)
64.9 ± 3.36 61.2 ± 3.68 63.1 ± 3.95 69.8 ± 3.96 0.4529 0.3941 0.7101 0.2006
Superoxide
dismutase 2 (SOD2)
5.09 ± 1.06b 5.66 ± 0.77bc 10.1 ± 0.63a 8.49 ± 0.7ac 0.0005 <0.001 0.517 0.1873
CD68 antigen
(CD68)
20.0 ± 10.4ab 8.75 ± 8.28b 30.9 ± 11.9a 29.1 ± 14.8a 0.0121 0.0027 0.1717 0.3142
Chemokine (C-C
motif) ligand 2
(MCP1)
0.94 ± 0.45 0.77 ± 0.25 1.45 ± 0.28 1.55 ± 1.77 0.3467 0.0898 0.7011 0.9267
Serum amyloid A
(SAA)
0.47 ± 0.29 0.51 ± 0.36 2.13 ± 3.83 2.70 ± 2.69 0.2919 0.0684 0.7926 0.7615
Geneexpression wasdeterminedusingthe2−ΔCt formula where ΔCt = ( C tt a r g e tg e n e −Ct 18S).Valuesare means ±standarderrorsfor 4–7 micepergroup.
Mean values within a row sharing a same superscript letter, or without superscript letter, were not signiﬁcantly diﬀerent at P < 0.05.
Table 5: Plasma concentrations of amino acid involved incysteine metabolism in WT and PPARα-null(KO)mice fed diets containing either
saturated FA (COCO diet) or ALA (LIN diet) for 8 weeks.
WT KO P values
COCO LIN COCO LIN ANOVA Genotype
(G)
Diet
(D)
Interaction
G∗D
Cysteine 16.3 ± 3.64 15.0 ± 2.12 17.2 ± 2.71 17.6 ± 3.87 0.9574 0.6144 0.8946 0.7949
Glycine 231 ± 17.3a 219 ± 14.26ab 170 ± 5.85b 214 ± 16.3ab 0.0236 0.0250 0.2603 0.0600
L-glutamic
acid
23.6 ± 1.20 23.9 ± 3.09 21.5 ± 1.38 19.4 ± 1.20 0.3186 0.0800 0.6746 0.5300
Methionine 39.8 ± 1.89 38.9 ± 2.07 47.1 ± 3.83 49.8 ± 5.32 0.0980 0.0150 0.8094 0.6253
Taurine 436 ± 59.8 511 ± 38.0 389 ± 43.0 366 ± 22.4 0.1290 0.0403 0.5624 0.2797
Values are expressed in μM. Values are means ± standard errors for 7 mice per group. Mean values within a row sharing a same superscript letter, or without
superscript letter, were not signiﬁcantly diﬀerent at P < 0.05.
uric acid concentration. When compared to their WT coun-
terparts, PPARα KO mice exhibited a higher plasma uric acid
concentration. However, due to a signiﬁcant genotype∗diet
interaction, this concentration was aﬀected only in mice fed
the COCO diet.
3.3.3. Plasma Cytokines and Hormones (Table 6). Concentra-
tions of leptin, insulin, and PAI1 were neither aﬀected by the
diet nor by the genotype. Independently of the genotype,
adiponectine concentration was signiﬁcantly higher in the
LIN-fed mice diet than in the COCO-fed mice and tended
to decrease (P = 0.0596) in response to PPARα deﬁciency.
In contrast, MCP1 concentration was not aﬀected by the
diet, but signiﬁcantly decreased in PPARα-deﬁcient mice
compared to WT mice.
4. Discussion
PPARα KO has been previously shown to aﬀect fatty
acid metabolism [33] and glucose homeostasis [1, 38]. In
line with these observations, our experimental conditionsPPAR Research 7
Table 6:Plasmahormonesandcytokines concentrationsinWTandPPARα-null(KO)micefeddietscontainingeithersaturatedFA(COCO
diet) or ALA (LIN diet) for 8 weeks.
WT KO P values
COCO LIN COCO LIN ANOVA Genotype
(G)
Diet
(D)
Interaction
G∗D
Insulin (ng/mL) 1.68 ± 0.36 2.87 ± 0.54 2.66 ± 0.37 1.83 ± 0.77 0.2300 0.9510 0.7145 0.0531
Leptin (pg/mL) 222 ± 52.9 254 ± 71.54 179 ± 39.2 242 ± 57.9 0.7748 0.6541 0.4430 0.8041
Adiponectine
(mg/mL)
8.11 ± 1.03b 13.6 ± 1.37a 6.95 ± 0.45b 10.7 ± 0.81ab 0.0005 0.0596 0.0002 0.3990
MCP 1 (pg/mL) 20.2 ± 4.55 18.3 ± 1.75 10.3 ± 1.89 13.8 ± 1.69 0.1040 0.0338 0.8119 0.4066
PAI 1 (ng/mL) 1.53 ± 0.19 1.65 ± 0.31 0.97 ± 0.21 1.65 ± 0.43 0.2241 0.3203 0.1616 0.3120
Values are means ± standard errors for 7 mice per group. Mean values within a row sharing a same superscript letter, or without superscript letter, were not
signiﬁcantly diﬀerent at P < 0.05.
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Figure 2: Plasma concentrations of uric acid in WT and PPARα-
deﬁcient(KO)micefeddietscontainingeithersaturatedFA(COCO
diet) or ALA (LIN diet) for 8 weeks. Values are means ± standard
errors for 7 mice per group, ∗KO group signiﬁcantly diﬀerent from
WT group P < 0.05. Columns sharing a same superscript letter, or
without superscript letter, were not signiﬁcantly diﬀerent at P <
0.05.
reproduced the characteristic phenotypic alterations asso-
ciated with PPARα deﬁciency, which are similar to some
of those clustered in the metabolic syndrome, such as obe-
sity,hepatichypertrophy,hypertriglyceridemia,hypercholes-
terolemia, and glycemic dysregulation (Table 2). Because
alteration of glutathione metabolism is a common feature
of the metabolic syndrome [39], and since we and others
have previously shown that PPARα invalidation impacted
some speciﬁc amino acid metabolic pathways [6–9, 40],
investigating the eﬀects of PPARα deﬁciency on cysteine
metabolism and GSH status was especially relevant.
4.1. Consequences of PPARα Deﬁciency on GSH Metabolism.
Under our experimental conditions, PPARα invalidation
was primarily associated with an overall increase in the
hepatic pool of GSH (P < 0.0367, Table 3). The signiﬁcant
genotype ∗ diet interaction (P < 0.001) showed that this
was true only in mice fed the COCO diet, as discussed
below. An increase in GSH pool might reﬂect an increase
in GSH synthesis and/or a decrease in GSH utilization
(export and/or degradation). As concerns GSH synthesis, it
is regulated primarily by γGCL activity, cysteine availability,
and GSH feedback inhibition [41]. In PPARα-deﬁcient mice,
the increase in hepatic GSH pool could be directly related
to an enhanced synthesis from cysteine, as suggested by
their higher total γGCL activity (Figure 1(b)). In parallel,
PPARα invalidation was accompanied by a lower plasma
concentrationof one ofthe GSH precursors,glycine, butalso
oftaurine,whereasthatofmethionineincreased(Table 5).In
contrast, plasma concentration of cysteine was not aﬀected,
suggesting that cysteine availability was not limiting for
GSH synthesis. Our results on taurine are consistent with
the decrease in plasma taurine concentration and in CDO
mRNA level in the adipose tissue of obese mice [42]. The
blunting of cysteine to taurine ﬂux in the adipose tissue may
eventually result in a sparing of cysteine which could be used
for glutathione synthesis. Because part of glycine synthesis
involves methyl transfer from methionine, the decrease in
glycine,together with the increase in methionine, may reﬂect
alterationsinone-carbonmetabolism,asreportedinsubjects
with nonalcoholic hepatosteatitis [43].
In addition to an increase in synthesis rate, the higher
hepatic GSH pool in KO mice could also result from a
decreased utilization in antioxidant defences. Under our
experimental conditions, the level of GPX1 mRNA, the
major glutathione peroxidase isoform, was unaﬀected by
PPARα deﬁciency (Table 4). This is consistent with a pre-
vious study showing that GPX activity was not altered
in fasted PPARα KO mice [23] and suggests that ﬁbrate-
enhanced GPX activity found in human erythrocytes [24]
was PPARα independent, and probably involved complex
post-transcriptional regulations.
4.2. Interactions between Genotype and Diet. A secondary
aim of this study was to investigate the impact of n-3 PUFA,
the nutritional PPARα ligands, on GSH metabolism. In WT
mice, hepatic GSH concentration and pool are higher in
mice fed the LIN diet than in those fed the COCO diet.8 PPAR Research
This is consistent with previous studies suggesting that long-
chain n-3 PUFA may exert a beneﬁcial action on oxidative
stress by increasing total glutathione in a rat model of
chronic heart failure [26] and in cultured human ﬁbroblasts
[29]. However, to our knowledge, the present study is
the ﬁrst evidence that, in comparison with saturated fatty
acids, even a very low amount of ALA may exert the same
eﬀects on GSH metabolism as its long-chain derivatives.
We have shown previously that even a very low intake
of dietary ALA (identical to the present study) activates
typical targets of PPARα,s u c ha sC y p 4 a 1 4[ 9, 31]. However,
the mechanisms by which ALA regulates GSH metabolism
in WT mice remains speculative, since none of the genes
studied, and in particular γGCL, exhibited a diﬀerence in
mRNA level between the COCO and the LIN diet. Thus,
even if typical target genes of PPARα are activated by the
LIN diet, rich in 18:3 n-3, it is not possible to conclude on
a direct involvement of PPARα into the regulation of GSH
level by fatty acids. Other pleiotropic eﬀects of fatty acids
have to be investigated, such as modiﬁcations of membrane
microdomain composition (thus modulating receptors and
ion channels functioning) or regulation of downstream cell
signalling pathways.
Unexpectedly, the impact of the dietary fatty acid proﬁle
onGSHmetabolismwasevenmorepronouncedinKOmice.
Indeed, post-hoc analysis showed that PPARα deﬁciency
increased total GSH content only in COCO-fed mice, and
not in the LIN-fed mice. Speciﬁc activity and mRNA level
of γGCL were not aﬀected by PPARα deﬁciency in mice
fed the COCO diet (Figure 1(a) and Table 4). Thus, their
higher GSH content results not only from a diﬀerence in
liver weight, which was 50% higher in this group than in
the three other ones (Table 2), but also from their increased
GSH concentration (Table 3), suggesting that the increased
GSH pool in KO mice fed the COCO diet is diet speciﬁc. The
mechanisticreasonswhyGSHconcentrationincreasedinKO
mice when fed the COCO diet remain unclear, since γGCL
speciﬁc activity was the same as in their WT counterparts,
whereasGPxactivitywasnotaﬀectedbyPPARαdeﬁciency.It
may be hypothesised that, secondary to PPARα invalidation,
exportation of GSH into plasma towards extrahepatic tissues
is impaired in KO mice, which would functionally aﬀect
the antioxidative defences of the whole body. In contrast,
GSH concentration and pool were not signiﬁcantly aﬀected
by PPARα deﬁciency in mice fed the LIN diet (Table 3).
To our knowledge, the only other study having investigated
the consequence of PPARα deﬁciency on GSH metabolism
reported a signiﬁcant depletion (20–25%) in total hepatic
GSH content in fasted KO mice fed a standard rodent chow
[23]. The fatty acid composition of the diet did not ﬁgure
in this study, but was probably, as usual in standard rodent
chows, soy oil rich in n-6 PUFA. Taken together, our data
and the previous ones suggest that a diet in which the lipid
moiety is rich in saturated FA and poor in PUFA, such as the
COCO diet, makes the liver GSH pool sensitive to PPARα
invalidation, whereas PUFA would protect the mice against
the eﬀects of PPARα deﬁciency.
In addition to the changes in cysteine metabolism and
GSH status, PPARα deﬁciency seemed to alter some markers
of the oxidative and inﬂammatory status, in interaction with
dietary fatty acids. Indeed, Sod2 (but not Sod1) mRNA
level increased in KO mice, especially when fed the COCO
diet (Table 4), which indicates an activation of antioxidant
defences [44]. This is apparently inconsistent with the
enhanced Sod2 expression by fenoﬁbrate in mouse brain
microvessels [45] and with the decrease in SOD activity in
fasted PPARα KO mice compared to the WT ones [23].
As discussed above for GSH content, these discrepancies
may reﬂect an eﬀect of the dietary fatty acid proﬁle on
the response to oxidative stress of PPARα KO mice. In line
with the higher Sod2 expression in PPARα KO mice, we
also observed an increase in the plasma concentration of
uric acid, a widely recognized marker of oxidative stress
[46], with the same diet ∗ genotype interaction: this
concentration was 4-fold increased in KO mice fed the
COCO diet, but not in those fed the LIN diet (Figure 2).
To our knowledge, this is the ﬁrst evidence of the impact
of PPARα deﬁciency of plasma uric acid concentration, in
interaction with the dietary fatty acid proﬁle. Altogether,
these two markers (hepatic Sod2 mRNA level and plasma
uric acid concentration) support the existence of a mild
oxidative stress in PPAR KO mice, which is mitigated by
the LIN diet. This is consistent with the previously reported
prevention of hepatic steatosis in PPAR KO mice by ALA
[30, 31]. Triglyceride accumulation in the liver is known
to trigger oxidative stress, which in turn contributes to the
pathogenesis of nonalcoholic steatohepatitis [47]. Therefore,
a decrease in fatty acid accumulation in response to ALA
feeding is expected to mitigate the oxidative stress resulting
from PPARα invalidation.
While PPAR deﬁciency induced a mild oxidative stress,
evidences for inﬂammation were less conclusive, since the
plasma concentration of both the proinﬂammatory cytokine
MCP1 and the anti-inﬂammatory adipokine, adiponectine,
was decreased, whereas PAI1 concentration did not change
(Table 6). In the liver, mRNA levels of CD68, SAA, and
MCP1 increased in KO mice, but the diﬀerence with WT
mice was signiﬁcant for CD68 only. Taken together, these
results suggest a mild inﬂammatory status in response to
PPARα invalidation. This is consistent with previous results
reporting that obesity-induced inﬂammation is aggravated
in PPAR-deﬁcient mice [48]. Finally, whatever the geno-
type, the plasma concentration of adiponectine, an anti-
inﬂammatoryadipokine,washigherinmicefedtheLINdiet,
suggesting an inﬂuence of the fatty acid proﬁle of the diet,
which is PPARα independent.
5. Conclusion
Under our experimental conditions, and in accordance
with a previous study [23], PPARα deﬁciency seemed to
induce an oxidative and inﬂammatory stress in the liver, as
evidenced by the higher values of hepatic GSH pool and
concentration, total γGCL activity, Sod2 mRNA level, and
plasma uric acid concentration. However, the phenotypic
consequences of PPARα deﬁciency depended, as last partly,
on the dietary fatty acid proﬁle. Indeed, most increasesPPAR Research 9
observed in KO mice fed the COCO diet (hepatic GSH pool
and concentration, total γGCL activity, Sod2 mRNA level,
and plasma uric acid concentration) were alleviated, or even
absent, in mice fed the LIN diet, suggesting that ALA would
be protective against these eﬀectsof PPARα invalidation. The
reasons of this diet-based sensitivity remains unclear, but it
is likely that it is not directly related to the PPARα deﬁciency.
More probably, it is secondary to the previously described
eﬀects of dietary fatty acids on hepatic steatosis in PPARα
KO mice [30, 31]. Indeed, this hepatic steatosis occurred in
KO mice fed a SFA-containing diet, but was alleviated, and
evenabsent, in those fedaPUFA-containing diet. Itmaythus
be hypothesized that the beneﬁcial eﬀects of dietary PUFA
on liver metabolism in KO mice, even in low amounts, may
be accounted for by a protection against lipid accumulation,
resulting in lower lipotoxicity and oxidative stress than with
SFA.
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